Julie Rubinstein compensation by year
Adaptive Biotechnologies Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $542,383 |
| Bonus | $0 |
| Stock awards | $3,783,500 |
| Option awards | $0 |
| Non-equity incentive | $273,180 |
| Pension and deferred compensation | $0 |
| All other | $4,932 |
| Total | $4,603,995 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptive Biotechnologies Corp DEF 14A filed April 24, 2026, accession 0001193125-26-177409, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 350,000 | $5,684,000 | — |
| RSU | 306,250 | $4,973,500 | — |
| RSU | 66,490 | $1,079,798 | — |
| RSU | 46,335 | $752,480 | — |
| Option | 62,360 | — | $8.46 |
| Option | 28,959 | — | $12.14 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptive Biotechnologies Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
12 Form 4 lines since the FY2025 proxy (filed April 24, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-04-27 | Exercise or conversion | 10b5-1 | 14,707 | $8.46 | 396,839 |
| 2026-04-27 | Sale | 10b5-1 | 19,037 | $14.23 | 377,802 |
| 2026-04-27 | Exercise or conversion derivative | 10b5-1 | 14,707 | $0.00 | 45,731 |
| 2026-04-24 | Exercise or conversion | 10b5-1 | 14,722 | $8.46 | 401,192 |
| 2026-04-24 | Exercise or conversion derivative | 10b5-1 | 14,722 | $0.00 | 60,438 |
| 2026-04-24 | Sale | 10b5-1 | 19,060 | $14.02 | 382,132 |
| 2026-04-23 | Exercise or conversion | 10b5-1 | 14,722 | $8.46 | 405,530 |
| 2026-04-23 | Sale | 10b5-1 | 19,060 | $13.74 | 386,470 |
The 8 most recent of 12 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Adaptive Biotechnologies’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Chad Robins | Chief Executive Officer and Chairman | $9,081,690 |
| Harlan Robins | Chief Scientific Officer | $8,509,575 |
| Julie Rubinstein · this page | President and Chief Operating Officer | $4,603,995 |
| Susan Bobulsky | Chief Commercial Officer, MRD | $3,547,558 |
| Kyle Piskel | Chief Financial Officer | $3,310,729 |
The full Adaptive Biotechnologies compensation record
free company briefThis page is one person within Adaptive Biotechnologies's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Adaptive Biotechnologies's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptive Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat